Impli focuses on offering a more convenient and effective method of monitoring hormone levels in women receiving infertility treatment. CERES is a subdermal device and a smartphone app as an alternative to frequent blood tests.
Female Fertility is fundamental to Europe’s future. Birth rates are at an all-time low while the average age in motherhood continues to increase. For women that need it, access to effective infertility treatment is vitally important; at present, ART only has a 15-30% success rate. Impli aims to create a platform to provide convenient and immediate access to hormonal health for reproduction but is also essential for contraception, menopause and female endocrine system disorders.
Currently, IVF treatments require females to undergo blood analysis every two days. This causes significant inconvenience. However, it is necessary to get more accurate results and outcomes and adapt clinical protocols during treatment. Females are already using other technologies to track hormone levels, such as Urine strips to measure the presence of luteinizing hormone capturing saliva to measure progesterone levels and temperature with wearables to evidence ovulation cycles.
There are several reasons why implantable sensors are required in remote diagnostics. Unlike wearable and portable sensors, they generate more accurate real-time results of highly specific biomarkers. Furthermore, they are genuinely remote and don’t require charging and drive significant patient adherence, therefore offering females undergoing reproductive treatment more freedom.